In this podcast, PharmaVentures’ deal experts discuss how to navigate risks in times of increased uncertainty.

Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about how companies can navigate risk and even deploy new strategies in times of increased uncertainty. With the threat of tariffs, a global trade war and unease in the financial markets this podcast explores the ways companies can gain advantage over their competitors and survive when geo-politics and high levels of volatility in the financial markets throws chaos and uncertainty into strategies adopted and deployed in more normal times.

Listen here:

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewee:

Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.

Over a period of three decades, he has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.

PharmaVentures Podcast Series, Edition 1

Buy Side Search and Find Mandates: the process for acquiring or licensing rights to companies or assets successfully

Presented by Adrian Dawkes

In this podcast, PharmaVentures’ deal experts discuss the process of helping clients in the life sciences industry acquire or license assets or rights in specific markets or whole companies.

What does this podcast address?

• Why do pharmaceutical companies licence and buy new assets?
• How does the process work?
• How will you know if it’s a good or a bad asset?
• What is the benefit of using advisors like PharmaVentures to help with Search and Find mandates?
• What advice should you heed if you are thinking about embarking on acquiring or licensing an asset on a search and find project?

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewees:

Kyriakos Tzafestas is a Director at PharmaVentures.

Prior to joining PharmaVentures, Kyriakos was a life sciences consultant working with biotech companies and early-stage technologies on projects encompassing market analysis, competitive intelligence, opportunity assessment, commercialisation roadmaps, patent landscaping, valuations, and business development for research collaborations and licensing opportunities. Before commencing his professional career, Kyriakos completed a Master of Biotechnology (Distinction) at the University of Glasgow and obtained a PhD in Molecular Biology from the University of York.

Ross Jenkins is a Senior Analyst at PharmaVentures with previous experience in diagnostic start-ups and commercialisation.

Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time, he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.

PharmaVentures Podcast Series, Edition 17

Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking. In particular, why innovator biotechs and their investors are weaker when they underestimate the significance of both understanding and communicating their commercial strategy for their lead assets in negotiations.

Hear about:

• Failing to understand the inherent risks at the commercial stage is a failure of investment logic.
• Why you shouldn’t expect a potential partner to have any answers to the commercial path and success of your asset
• Why you should know where your assets fit in the market landscape and what differentiates it commercially.
• How to apply commercial strategic thinking to very early-stage assets.
• How planning to avoid commercial risk reduces investment risk.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 16

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into;

• Where AI is benefiting drug discovery processes today?
• How will it be used in the future, will we get better drugs faster?
• Can it replace the need for human involvement?
• Will AI impact on the discovery and use of new biomarkers?

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 15

Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape. Key topics include;

• Is the M&A landscape recovering and will we see record activity again?
• How has the big pharma model changed and what is the impact on deal making?
• What is the direction of travel for deal volumes and values?
• How do biotechs position themselves to get the best deals?
• Who holds the upper hand, buyers or sellers?
• What does M&A look like for hot and emerging sectors such as AI drug discovery and Advanced Therapies?

To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com

About the Interviewees:

Soren Demin is a Managing Director at PharmaVentures, where he excels in creating and unlocking value for clients through M&A, business development, and licensing. He joined PharmaVentures in 2024, bringing over 15 years of global experience in the biopharma industry.

Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimized solutions.

Before this role, Soren served as Chief Business Officer at the private equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations and directed product development and manufacturing. Previously, Soren was part of Mitsubishi Tanabe and the Piramal Group

Soren began his M&A career at Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 14

Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss:

• Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing
• Its application to specific medical models and therapy areas – including personalised medicine, oncology, and Alzheimer’s
• Key players in the area, and their commercial models
• The importance of diagnostics working hand-in-hand with therapeutics
• Licensing and M&A transactions, and the potential deal values in the future

To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com

About the Interviewees:

Andreas Katsiamides is an Associate at PharmaVentures.

He has experience in Molecular Biology and Medical Diagnostics. Prior to joining PharmaVentures, Andreas worked in competitive intelligence consulting firms, supporting with commercial/competitor due diligence and opportunity and threat assessments across a range of therapy areas including oncology, personalised healthcare, and infectious and rare diseases.

Andreas holds a BSc in Molecular Genetics and Pharmacology and a PhD in Molecular Neurobiology, both from the University of King’s College London (UK).

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.